Loading...
•
Dec 31, 2022
ANI Pharmaceuticals Q4 2022 Earnings Report
ANI Pharmaceuticals reported record fourth quarter financial results and achieved full year 2022 revenue milestone.
Key Takeaways
ANI Pharmaceuticals reported Q4 net revenues of $94.2 million, a net loss available to common shareholders of $(4.7) million, and an adjusted non-GAAP diluted earnings per share of $0.76. The company's full-year 2022 net revenues reached $316.4 million.
Q4 net revenues reached $94.2 million, marking a 54.7% growth.
Adjusted non-GAAP diluted earnings per share for Q4 was $0.76.
Full year 2022 net revenues were $316.4 million.
Purified Cortrophin Gel full-year 2022 net sales reached $41.7 million.
ANI Pharmaceuticals
ANI Pharmaceuticals
ANI Pharmaceuticals Revenue by Segment
Revenue by Segment
Generic Pharmaceutical Products Revenue
CapyFin.com Forward Guidance
ANI Pharmaceuticals initiates total Company net revenue guidance of $360 million to $385 million; adjusted non-GAAP EBITDA guidance of $78 million to $88 million; adjusted non-GAAP earnings per share of $2.09 to $2.59.
Positive Outlook
- Total Company expected Net Revenues between $360.0 million and $385.0 million, representing approximately 14% to 22% growth as compared to $316.4 million recognized in 2022
- Cortrophin specific revenue guidance between $80.0 million to $90.0 million, representing 92% to 116% growth as compared to $41.7 million recognized in 2022
- Total Company non-GAAP Gross Margin between 59.5% and 61.0%
- Total Company Adjusted non-GAAP EBITDA between $78.0 million and $88.0 million
- Adjusted non-GAAP Diluted Earnings per Share between $2.09 and $2.59